- Previous Close
0.6800 - Open
0.6631 - Bid 0.6800 x 40000
- Ask 0.6869 x 40000
- Day's Range
0.6631 - 0.7300 - 52 Week Range
0.6080 - 2.2000 - Volume
12,521 - Avg. Volume
66,045 - Market Cap (intraday)
53.561M - Beta (5Y Monthly) 1.08
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2600 - Earnings Date Jun 25, 2025 - Jun 30, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.25
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops bizaxofusp (MDNA55), an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; MDNA113, a masked bi-functional anti-PD1-IL2 Superkine for various solid tumors; and MDNA132, an IL-13 Superkine for various tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, inhibitors, antibodies, cytokines, or other Superkines Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.
www.medicenna.comRecent News: MDNAF
View More
Performance Overview: MDNAF
Trailing total returns as of 3/31/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MDNAF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MDNAF
View MoreValuation Measures
Market Cap
53.29M
Enterprise Value
32.56M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
4.38
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-42.08%
Return on Equity (ttm)
-149.09%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-26.9M
Diluted EPS (ttm)
-0.2600
Balance Sheet and Cash Flow
Total Cash (mrq)
30M
Total Debt/Equity (mrq)
1.00%
Levered Free Cash Flow (ttm)
-11.54M